{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:32:35Z","timestamp":1793496755030,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome caused by pathogenic variants in the NF1 gene. It exhibits highly variable and unpredictable clinical manifestations involving multiple organ systems, with caf\u00e9-au-lait macules and multiple neurofibromas being hallmark features. Epilepsy represents a common central nervous system complication in NF1, though its underlying mechanisms remain poorly understood. NF1 patients with epilepsy exhibit a higher prevalence of developmental delay and learning disabilities. Early identification and personalized therapy are critical for optimal management of this patient population. This review aims to synthesize published literature on the disease, thereby providing a comprehensive, detailed, and updated overview of its entire clinical spectrum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive literature search in PubMed, China National Knowledge Infrastructure, and Chinese Medical Association Journal Full-text Database for original research articles with available full-text manuscripts in English or Chinese, with a publication cutoff date of March 1, 2025. Our search strategy employed the terms \u201cneurofibromatosis type 1\u201d OR \u201cNF1\u201d combined using the Boolean operator AND with \u201cepilepsy\u201d OR \u201cseizure.\u201d Priority was given to studies published in the last decade, though seminal earlier research was also incorporated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>An extensive bibliography was researched and summarized in the review. Epilepsy represents a common central nervous system complication in NF1, though its underlying mechanisms remain poorly understood. NF1-associated epilepsy demonstrates diverse seizure semiologies, with focal seizures being the most prevalent phenotype. Although the majority of patients demonstrate favorable responses to oral anti-seizure medications, those with structural brain abnormalities frequently develop drug-resistant epilepsy. Notably, a subset of these patients may achieve significant seizure reduction or complete remission through surgical intervention when the epileptogenic zone is clearly delineated. Furthermore, while targeted therapies remain an active area of investigation, their application in NF1-associated epilepsy remains supported only by case report-level evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This review comprehensively summarizes current knowledge regarding the pathogenesis, clinical characteristics, diagnostic approaches, and therapeutic strategies for NF1-related epilepsy, aiming to optimize diagnostic accuracy and treatment outcomes for affected individuals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1640309","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:20:40Z","timestamp":1755246040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances of epilepsy associated with neurofibromatosis type 1"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.12376\/j.issn.2097-0501.2023.02.009","article-title":"Multidisciplinary Diagnosis and Treatment Guidelines for Neurofibromatosis Type I (2023 Edition)","volume":"2","year":"2023","journal-title":"J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/JMDH.S454921","article-title":"Epidemiology and outcomes of Neurofibromatosis type 1 (NF-1): multicenter tertiary experience","volume":"17","author":"Almuqbil","year":"2024","journal-title":"J Multidiscip Healthc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00381-020-04710-7","article-title":"Epilepsy in NF1: a systematic review of the literature","volume":"36","author":"Bernardo","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1284574","DOI":"10.3389\/fneur.2024.1284574","article-title":"Early-life immune activation is a vulnerability factor for adult epileptogenesis in neurofibromatosis type 1 in male mice","volume":"15","author":"Faidi","year":"2024","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00381-021-05343-0","article-title":"Hippocampal sclerosis and epilepsy surgery in neurofibromatosis type 1: case report of a 3-year-old child explored by SEEG and review of the literature","volume":"38","author":"Sculier","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"113373","DOI":"10.1016\/j.expneurol.2020.113373","article-title":"Increased epileptogenicity in a mouse model of neurofibromatosis type 1","volume":"331","author":"Sabetghadam","year":"2020","journal-title":"Exp Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yebeh.2017.05.011","article-title":"Epilepsy in neurofibromatosis type 1","volume":"73","author":"Pecoraro","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13052-018-0477-x","article-title":"Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?","volume":"44","author":"Santoro","year":"2018","journal-title":"Ital J Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/brain\/awac117","article-title":"Somatic variants in diverse genes leads to a spectrum of focal cortical malformations","volume":"145","author":"Lai","year":"2022","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/onc.2016.464","article-title":"The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas","volume":"36","author":"Pemov","year":"2017","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1001\/jamaneurol.2023.0473","article-title":"Contribution of somatic Ras\/Raf\/mitogen-activated protein kinase variants in the Hippocampus in drug-resistant mesial temporal lobe epilepsy","volume":"80","author":"Khoshkhoo","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40478-018-0551-z","article-title":"The genetic landscape of ganglioglioma","volume":"6","author":"Pekmezci","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00401-019-02002-2","article-title":"An update on the central nervous system manifestations of neurofibromatosis type 1","volume":"139","author":"Nix","year":"2020","journal-title":"Acta Neuropathol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"106144","DOI":"10.1016\/j.nbd.2023.106144","article-title":"mTOR pathway: insights into an established pathway for brain mosaicism in epilepsy","volume":"182","author":"Gerasimenko","year":"2023","journal-title":"Neurobiol Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"106190","DOI":"10.1016\/j.eplepsyres.2019.106190","article-title":"Increased seizure susceptibility in a mouse model of neurofibromatosis type 1","volume":"156","author":"Rizwan","year":"2019","journal-title":"Epilepsy Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","article-title":"Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis","volume":"69","author":"DeClue","year":"1992","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eplepsyres.2013.02.021","article-title":"Epilepsy surgery in Neurofibromatosis type 1","volume":"105","author":"Barba","year":"2013","journal-title":"Epilepsy Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.neurol.2011.04.009","article-title":"Seizures in neurofibromatosis. What is the risk?","volume":"167","author":"Drouet","year":"2011","journal-title":"Rev Neurol (Paris)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12883-020-01911-0","article-title":"A novel RAB39B mutation and concurrent de novo NF1 mutation in a boy with neurofibromatosis type 1, intellectual disability, and autism: a case report","volume":"20","author":"Santoro","year":"2020","journal-title":"BMC Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.seizure.2011.04.016","article-title":"Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects","volume":"20","author":"Hsieh","year":"2011","journal-title":"Seizure"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/epd2.20180","article-title":"Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-developmental and epileptic encephalopathy and optic pathway glioma","volume":"26","author":"Barri\u00e8re","year":"2024","journal-title":"Epileptic Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejpn.2023.08.005","article-title":"Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy","volume":"51","author":"Specchio","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","article-title":"The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1","volume":"15","author":"Li","year":"2005","journal-title":"Curr Biol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2008.09.060","article-title":"Neurofibromin regulation of ERK signaling modulates GABA release and learning","volume":"135","author":"Cui","year":"2008","journal-title":"Cell"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1523\/JNEUROSCI.3096-13.2014","article-title":"Neurofibromin is the major ras inactivator in dendritic spines","volume":"34","author":"Oliveira","year":"2014","journal-title":"J Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1007\/s12035-015-9503-9","article-title":"Neurofibromin regulates seizure attacks in the rat pilocarpine-induced model of epilepsy","volume":"53","author":"Ren","year":"2016","journal-title":"Mol Neurobiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1007\/s12035-016-9907-1","article-title":"Sensitization of ion channels contributes to central and peripheral dysfunction in Neurofibromatosis type 1","volume":"54","author":"Moutal","year":"2017","journal-title":"Mol Neurobiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2478\/v10134-010-0025-8","article-title":"Altered calcium currents and axonal growth in nf1 haploinsufficient mice","volume":"1","author":"Wang","year":"2010","journal-title":"Transl Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jocn.2016.10.048","article-title":"Hippocampal sclerosis and associated focal cortical dysplasia-related epilepsy in neurofibromatosis type I","volume":"37","author":"Gales","year":"2017","journal-title":"J Clin Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1542\/peds.104.4.e49","article-title":"Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential?","volume":"104","author":"Griffiths","year":"1999","journal-title":"Pediatrics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00247-006-0267-2","article-title":"Age-related findings on MRI in neurofibromatosis type 1","volume":"36","author":"Gill","year":"2006","journal-title":"Pediatr Radiol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2329048X221131445","DOI":"10.1177\/2329048X221131445","article-title":"Epilepsy and electroencephalogram characteristics in children with Neurofibromatosis type 1, what we have learned from a tertiary center five years' experience","volume":"9","author":"Khair","year":"2022","journal-title":"Child Neurol Open"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3760\/cma.j.cn112140-20230829-00146","article-title":"Clinical characteristics of epileptic seizure in neurofibromatosis type 1 in 15 cases","volume":"61","author":"Wu","year":"2023","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1528-1157.1993.tb00437.x","article-title":"Patterns of seizures observed in association with neurofibromatosis 1","volume":"34","author":"Korf","year":"1993","journal-title":"Epilepsia"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.yebeh.2019.06.022","article-title":"Epilepsy in neurofibromatosis type 1: diffuse cerebral dysfunction?","volume":"98","author":"Serdaroglu","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1111\/epi.12348","article-title":"Epilepsy in individuals with neurofibromatosis type 1","volume":"54","author":"Ostendorf","year":"2013","journal-title":"Epilepsia"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jns.2011.03.048","article-title":"Electrophysiological findings in neurofibromatosis type 1","volume":"306","author":"Yerdelen","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"100374","DOI":"10.1016\/j.ebr.2020.100374","article-title":"Rapid ictal transition of focal epilepsy to infantile spasms in neurofibromatosis type 1 captured with EEG","volume":"14","author":"Patel","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"960746","DOI":"10.1155\/2015\/960746","article-title":"A potential role for felbamate in TSC- and NF1-related epilepsy: a case report and review of the literature","volume":"2015","author":"Mishal","year":"2015","journal-title":"Case Rep Neurol Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1469-8749.1995.tb11943.x","article-title":"Neuropsychological function and MRI abnormalities in neurofibromatosis type 1","volume":"37","author":"Joy","year":"1995","journal-title":"Dev Med Child Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1542\/peds.105.3.608","article-title":"Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children","volume":"105","author":"DeBella","year":"2000","journal-title":"Pediatrics"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"107336","DOI":"10.1016\/j.eplepsyres.2024.107336","article-title":"Epilepsy in neurofibromatosis type 1: prevalence, phenotype, and genotype in adults","volume":"202","author":"H\u00e9bert","year":"2024","journal-title":"Epilepsy Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/nu16091258","article-title":"Ketogenic diet in the treatment of epilepsy","volume":"16","author":"Borowicz-Reutt","year":"2024","journal-title":"Nutrients"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","article-title":"Tuberous sclerosis complex and the ketogenic diet","volume":"46","author":"Kossoff","year":"2005","journal-title":"Epilepsia"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/nu12061809","article-title":"Efficacy and safety of a ketogenic diet in children and adolescents with refractory epilepsy-a review","volume":"12","author":"Wells","year":"2020","journal-title":"Nutrients"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/17562864211031100","article-title":"Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine","volume":"14","author":"Schubert-Bast","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"863826","DOI":"10.3389\/fneur.2022.863826","article-title":"Ketogenic diet therapy for drug-resistant epilepsy and cognitive impairment in children with tuberous sclerosis complex","volume":"13","author":"Fang","year":"2022","journal-title":"Front Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/j.1528-1167.2011.02981.x","article-title":"The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway","volume":"52","author":"McDaniel","year":"2011","journal-title":"Epilepsia"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.mce.2015.09.012","article-title":"Ketogenic diet delays the phase of circadian rhythms and does not affect AMP-activated protein kinase (AMPK) in mouse liver","volume":"417","author":"Genzer","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/10600280211046298","article-title":"A review of selumetinib in the treatment of Neurofibromatosis type 1-related plexiform neurofibromas","volume":"56","author":"Anderson","year":"2022","journal-title":"Ann Pharmacother"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00381-022-05571-y","article-title":"Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1","volume":"38","author":"Cantor","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/neuonc\/nou329","article-title":"Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jaad.2020.07.105","article-title":"Neurofibromatosis type 1: new developments in genetics and treatment","volume":"84","author":"Wilson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3760\/cma.j.issn.0253-3006.2019.02.018","article-title":"Advances in targeted therapy for neurofibromatosis type I-related tumors","volume":"40","author":"Liu","year":"2019","journal-title":"Chinese J Pediatr Surg"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1640309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:20:43Z","timestamp":1755246043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1640309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":57,"alternative-id":["10.3389\/fneur.2025.1640309"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1640309","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1640309"}}